# Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

> **NCT05569512** · PHASE1 · TERMINATED · sponsor: **Malika Kapadia** · enrollment: 1 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Pediatric Cancer

## Interventions

- **DRUG:** Uproleselan
- **DRUG:** Fludarabine
- **DRUG:** Clofarabine
- **DRUG:** Busulfan

## Key facts

- **NCT ID:** NCT05569512
- **Lead sponsor:** Malika Kapadia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-06
- **Primary completion:** 2023-10-05
- **Final completion:** 2023-12-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for NCT05569512 following company restructuring. This notification came ahead of the study meeting criteria to progress from Phase 1 to Phase 2.
- **Last updated:** 2024-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05569512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05569512, "Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05569512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*